Table 2.
Clinical applications of [99mTc]Tc-FAPI tracers in oncology
| Author | Year/country | Compound | Administered activity | Imaging Protocol | Clinical setting | Patient cohort | Comment |
|---|---|---|---|---|---|---|---|
| Jia et al. (2023) | 2023/China | FAPI-04 | 790.4–930.2 MBq | Biodistribution: WB at 10, 30, 90, 150 and 240 min (n = 4) Diagnostics: WB + SPECT/CT at 60–90 p.i. (n = 40) | Digestive system tumors | 40 | [99mTc]Tc-HFAPi SPECT/CT showed high diagnostic performance, superior to that of ce-CT in the assessment of distant metastases (in particular liver and bone) |
| Ruan et al. (2022, 2023a, 2023b) | 2023/China | DP-FAPI | 828.8–1128.5 MBq | Biodistribution: WB at 0, 1, 2, 4, 8, and 24 h Diagnostics: SPECT/CT at 2 h | Gastrointestinal tumors | 7 (4 healthy volunteers and 3 oncological) | [99mTc]Tc-DP-FAPI was well-tolerated by patients and exhibited high diagnostic performance for the detection of gastrointestinal tumors |
| Coria-Domínguez et al. (2022) | 2022/Mexico | iFAP | 740 MBq | Biodistribution: WB at 0.5, 2, 4 and 24 h Diagnostics: SPECT/CT at 3 h | healthy volunteers; cervical, lung and breast cancer | 9 (6 healthy volunteers and 3 oncological) | [99mTc]Tc-iFAP uptake intensity (cervical > breast > lung) resulted inverse to that of [18F]FDG (lung > breast > cervical) |
| Vallejo-Armenta et al. (2022) | 2022/Mexico | iFAP | 735 ± 63.5 MBq | Diagnostics: SPECT/CT at 2 h | 5 brain tumors (gliomas) and 27 tumors of various districts | 32 | [99mTc]Tc-iFAP SPECT/CT detected less metastases than [18F]FDG PET/CT, but showed good performances in the discrimination of high-grade vs low-grade gliomas |